1.Hoeben A, Joosten EA, van den Beuken-van Everdingen MH. Personalized medicine: recent progress in cancer therapy. Cancers. 2021;13(2):242.
2.Capella MP, Esfahani K. A Review of Practice-Changing Therapies in Oncology in the Era of Personalized Medicine. Current Oncology. 2024;31(4):1913-9.
3.Jain KK, Jain KK. Personalized immuno-oncology. Textbook of Personalized Medicine. 2021:479-508.
4.Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE open medicine. 2021;9:20503121211034366.
5.Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer treatment reviews. 2020;86:102019.
6.Hassan M, Awan FM, Naz A, deAndrés-Galiana EJ, Alvarez O, Cernea A, et al. Innovations in genomics and big data analytics for personalized medicine and health care: A review. International journal of molecular Sciences. 2022;23(9):4645.
7.Fujiwara Y, Kato S, Kurzrock R. Evolution of precision oncology, personalized medicine, and molecular tumor boards. Surgical Oncology Clinics. 2024;33(2):197-216.
8.Dalghi E. Bridging Genomics and Oncology: Molecular Approaches to Personalized Medicine. International Journal of BioLife Sciences (IJBLS). 2023;2(2):281-90.
9.Braig ZV. Personalized medicine: From diagnostic to adaptive. biomedical journal. 2022;45(1):132-42.
10.Schmidt KT, Chau CH, Price DK, Figg WD. Precision oncology medicine: the clinical relevance of patient‐specific biomarkers used to optimize cancer treatment. The Journal of Clinical Pharmacology. 2016;56(12):1484-99.
11.Mateo J, Steuten L, Aftimos P, André F, Davies M, Garralda E, et al. Delivering precision oncology to patients with cancer. Nature medicine. 2022;28(4):658-65.
12.Saeed RF, Awan UA, Saeed S, Mumtaz S, Akhtar N, Aslam S. Targeted therapy and personalized medicine.  Therapeutic Approaches in Cancer Treatment: Springer; 2023. p. 177-205.
13.Kalia M. Personalized oncology: Recent advances and future challenges. Metabolism. 2013;62:S11-S4.
14.Bao Y, Zhang D, Guo H, Ma W. Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine. Cancer Science. 2024;115(4):1060-72.
15.Fernández-Lázaro D, García Hernández JL, García AC, Córdova Martínez A, Mielgo-Ayuso J, Cruz-Hernández JJ. Liquid biopsy as novel tool in precision medicine: Origins, properties, identification and clinical perspective of cancer’s biomarkers. Diagnostics. 2020;10(4):215.
16.Hussen BM, Abdullah ST, Salihi A, Sabir DK, Sidiq KR, Rasul MF, et al. The emerging roles of NGS in clinical oncology and personalized medicine. Pathology-Research and Practice. 2022;230:153760.
17.Normanno N, Rachiglio AM, Roma C, Fenizia F, Esposito C, Pasquale R, et al. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. Journal of cellular biochemistry. 2013;114(3):514-24.
18.Morganti S, Tarantino P, Ferraro E, D’Amico P, Viale G, Trapani D, et al. Role of next-generation sequencing technologies in personalized medicine. P5 eHealth: An Agenda for the Health Technologies of the Future. 2020:125-54.
19.Morash M, Mitchell H, Beltran H, Elemento O, Pathak J. The role of next-generation sequencing in precision medicine: a review of outcomes in oncology. Journal of personalized medicine. 2018;8(3):30.
20.Adeniji AA, Dulal S, Martin MG. Personalized medicine in oncology in the developing world: barriers and concepts to improve status quo. World journal of oncology. 2021;12(2-3):50.
21.Gil J, Laczmanska I, Pesz KA, Sasiadek MM. Personalized medicine in oncology. New perspectives in management of gliomas. Contemporary Oncology/Współczesna Onkologia. 2018;2018(1):1-2.
22.Da Silva RCDS, de Andrade Simon N, Dos Santos AA, Olegário GDM, Da Silva JF, Sousa NO, et al. Personalized medicine: Clinical oncology on molecular view of treatment. World Journal of Clinical Oncology. 2024;15(8):992.
23.Garattini L, Curto A, Freemantle N. Personalized medicine and economic evaluation in oncology: all theory and no practice? : Taylor & Francis; 2015. p. 733-8.
24.Carneiro BA, Costa R, Taxter T, Chandra S, Chae YK, Cristofanilli M, et al. Is personalized medicine here? Oncology. 2016;30(4):293-.
25.Israel O, Keidar Z, Iosilevsky G, Bettman L, Sachs J, Frenkel A, editors. The fusion of anatomic and physiologic imaging in the management of patients with cancer. Seminars in nuclear medicine; 2001: Elsevier.
26.Gonzalez de Castro D, Clarke P, Al‐Lazikani B, Workman P. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clinical Pharmacology & Therapeutics. 2013;93(3):252-9.
27.Yang S-R, Schultheis AM, Yu H, Mandelker D, Ladanyi M, Büttner R, editors. Precision medicine in non-small cell lung cancer: Current applications and future directions. Seminars in cancer biology; 2022: Elsevier.
28.Lei Y, Lei Y, Shi X, Wang J. EML4‑ALK fusion gene in non‑small cell lung cancer. Oncology letters. 2022;24(2):1-6.
29.Malone ER, Oliva M, Sabatini PJ, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome medicine. 2020;12:1-19.
30.Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, et al. Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: a meta‐analysis. International journal of cancer. 2017;140(12):2805-19.
31.Moorcraft SY, Gonzalez D, Walker BA. Understanding next generation sequencing in oncology: A guide for oncologists. Critical reviews in oncology/hematology. 2015;96(3):463-74.
32.Hinrichs JW, Marja van Blokland W, Moons MJ, Radersma RD, Radersma-van Loon JH, de Voijs CM, et al. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice. American journal of clinical pathology. 2015;143(4):573-8.
33.Misyura M, Zhang T, Sukhai MA, Thomas M, Garg S, Kamel-Reid S, et al. Comparison of next-generation sequencing panels and platforms for detection and verification of somatic tumor variants for clinical diagnostics. The Journal of Molecular Diagnostics. 2016;18(6):842-50.
34.Sie D, Snijders PJ, Meijer GA, Doeleman MW, van Moorsel MI, van Essen HF, et al. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. Cellular Oncology. 2014;37:353-61.
35.Su D, Zhang D, Chen K, Lu J, Wu J, Cao X, et al. High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods. Journal of Experimental & Clinical Cancer Research. 2017;36:1-12.
36.Yip S, Christofides A, Banerji S, Downes M, Izevbaye I, Lo B, et al. A Canadian guideline on the use of next-generation sequencing in oncology. Current Oncology. 2019;26(2):e241.
37.Hartmaier RJ, Charo J, Fabrizio D, Goldberg ME, Albacker LA, Pao W, et al. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies. Genome Medicine. 2017;9:1-9.
38.Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. Journal of clinical oncology. 2015;33(25):2753-62.
39.Le Tourneau C, Kamal M, Tsimberidou A-M, Bedard P, Pierron G, Callens C, et al. Treatment algorithms based on tumor molecular profiling: the essence of precision medicine trials. Journal of the National Cancer Institute. 2016;108(4):djv362.
40.Hess JM, Bernards A, Kim J, Miller M, Taylor-Weiner A, Haradhvala NJ, et al. Passenger hotspot mutations in cancer. Cancer Cell. 2019;36(3):288-301. e14.
41.Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019;575(7781):210-6.
42.Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature. 2018;555(7696):371-6.
43.Cavelier L, Ameur A, Häggqvist S, Höijer I, Cahill N, Olsson-Strömberg U, et al. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing. Bmc Cancer. 2015;15:1-12.
44.Nattestad M, Goodwin S, Ng K, Baslan T, Sedlazeck FJ, Rescheneder P, et al. Complex rearrangements and oncogene amplifications revealed by long-read DNA and RNA sequencing of a breast cancer cell line. Genome research. 2018;28(8):1126-35.
45.Tevz G, McGrath S, Demeter R, Magrini V, Jeet V, Rockstroh A, et al. Identification of a novel fusion transcript between human relaxin-1 (RLN1) and human relaxin-2 (RLN2) in prostate cancer. Molecular and Cellular Endocrinology. 2016;420:159-68.
46.Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England journal of medicine. 2012;366(10):883-92.
47.Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature. 2013;501(7467):355-64.
48.Lee C-k, Kim S, Lee JS, Lee JE, Kim S-m, Yang IS, et al. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. Lung Cancer. 2017;113:106-14.
49.Heitzer E, Haque IS, Roberts CE, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nature Reviews Genetics. 2019;20(2):71-88.
50.Rossi G, Ignatiadis M. Promises and pitfalls of using liquid biopsy for precision medicine. Cancer research. 2019;79(11):2798-804.
51.Scott SN, Ostrovnaya I, Lin CM, Bouvier N, Bochner BH, Iyer G, et al. Next‐generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non–muscle‐invasive urothelial carcinoma treated with bacille Calmette‐Guérin. Cancer Cytopathology. 2017;125(6):416-26.
52.Dietz S, Schirmer U, Mercé C, Von Bubnoff N, Dahl E, Meister M, et al. Low input whole-exome sequencing to determine the representation of the tumor exome in circulating DNA of non-small cell lung cancer patients. PloS one. 2016;11(8):e0161012.
53.Manier S, Park J, Capelletti M, Bustoros M, Freeman S, Ha G, et al. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nature communications. 2018;9(1):1691.
54.Witwer KW. Circulating microRNA biomarker studies: pitfalls and potential solutions. Clinical chemistry. 2015;61(1):56-63.
55.Dupont CA, Riegel K, Pompaiah M, Juhl H, Rajalingam K. Druggable genome and precision medicine in cancer: current challenges. The FEBS journal. 2021;288(21):6142-58.
56.Manchia M, Pisanu C, Squassina A, Carpiniello B. Challenges and future prospects of precision medicine in psychiatry. Pharmacogenomics and personalized medicine. 2020:127-40.
57.Belin L, Kamal M, Mauborgne C, Plancher C, Mulot F, Delord J-P, et al. Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial. Annals of Oncology. 2017;28(3):590-6.
58.Yang H-T, Shah RH, Tegay D, Onel K. Precision oncology: Lessons learned and challenges for the future. Cancer Management and Research. 2019:7525-36.
59.Kucherlapati R. Impact of precision medicine in oncology. The Cancer Journal. 2023;29(1):1-2.
60.Hamamoto R, Suvarna K, Yamada M, Kobayashi K, Shinkai N, Miyake M, et al. Application of artificial intelligence technology in oncology: Towards the establishment of precision medicine. Cancers. 2020;12(12):3532.
61.Fountzilas E, Tsimberidou AM, Vo HH, Kurzrock R. Clinical trial design in the era of precision medicine. Genome medicine. 2022;14(1):101.
62.Zhang Q, Fu Q, Bai X, Liang T. Molecular profiling–based precision medicine in cancer: a review of current evidence and challenges. Frontiers in oncology. 2020;10:532403.
63.Kruglyak KM, Lin E, Ong FS. Next-generation sequencing in precision oncology: challenges and opportunities. Expert review of molecular diagnostics. 2014;14(6):635-7.
64.Hartl D, de Luca V, Kostikova A, Laramie J, Kennedy S, Ferrero E, et al. Translational precision medicine: an industry perspective. Journal of translational medicine. 2021;19(1):245.
65.Rulten SL, Grose RP, Gatz SA, Jones JL, Cameron AJ. The future of precision oncology. International Journal of Molecular Sciences. 2023;24(16):12613.
66.Habeeb NW-A, Kulasingam V, Diamandis EP, Yousef GM, Tsongalis GJ, Vermeulen L, et al. The use of targeted therapies for precision medicine in oncology. Clinical Chemistry. 2016;62(12):1556-64.